Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?

Angiotensin converting enzyme (ACE) inhibitors have emerged as a significant advance in the treatment of heart failure; yet only a minority (i.e., 30% to 40%) of eligible patients are being treated with these drugs, and even among treated patients, the doses used in clinical practice are substantially lower than those used in the clinical trials that established the efficacy and safety of these agents. The preference for low doses is based on the belief that low and high doses exert similar benefits but that high doses produce more side effects. Yet, most studies indicate that large doses of ACE inhibitors produce greater hemodynamic and clinical effects than small doses, with no additional toxicity. However, it is uncertain whether the survival effects of these drugs are also related to dose. To address this question, a large multinational, double-blind clinical trial (Assessment of Treatment With Lisinopril and Survival [ATLAS]) was launched to compare the effects of low and high doses of the ACE inhibitor lisinopril on the survival of patients with heart failure. If the study demonstrates that large doses are needed to produce optimal effects on mortality, then the low dose strategies that are now widely used in clinical practice may be inadvertently nullifying the enormous potential benefits that ACE inhibitors might otherwise have on public health.

This article has been cited by other articles:

				A Y Patwala and D J Wright Device based treatment of heart failure Postgrad. Med. J., May 1, 2005; 81(955): 286 - 291. [Abstract] [Full Text] [PDF]

				R McMullan and B Silke A survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure Postgrad. Med. J., December 1, 2001; 77(914): 765 - 768. [Abstract] [Full Text] [PDF]

				D. P. Holst, D. Kaye, M. Richardson, H. Krum, D. Prior, A. Aggarwal, R. Wolfe, and P. Bergin Improved outcomes from a comprehensive management system for heart failure Eur J Heart Fail, October 1, 2001; 3(5): 619 - 625. [Abstract] [Full Text] [PDF]

				M. Gomberg-Maitland, D. A. Baran, and V. Fuster Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist Arch Intern Med, February 12, 2001; 161(3): 342 - 352. [Abstract] [Full Text] [PDF]

				B. M. Massie, P. W. Armstrong, J. G. F. Cleland, J. D. Horowitz, M. Packer, P. A. Poole-Wilson, and L. Ryden Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure: Results From the ATLAS Trial Arch Intern Med, January 22, 2001; 161(2): 165 - 171. [Abstract] [Full Text] [PDF]

				L Ryden, P.W Armstrong, J.G.F Cleland, J.D Horowitz, B.M Massie, M Packer, and P.A Poole-Wilson Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial Eur. Heart J., December 1, 2000; 21(23): 1967 - 1978. [Abstract] [PDF]

				F. Delahaye and G. de Gevigney Is the optimal dose of angiotensin-converting enzyme inhibitors in patients with congestive heart failure definitely established? J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2096 - 2097. [Full Text] [PDF]

				J. Vitovec, J. Spinar, and Czech and Slovak Investigator Group First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril Eur J Heart Fail, September 1, 2000; 2(3): 299 - 304. [Abstract] [Full Text] [PDF]

				T. Shinke, H. Takaoka, M. Takeuchi, K. Hata, H. Kawai, H. Okubo, Y. Kijima, T. Murata, and M. Yokoyama Nitric Oxide Spares Myocardial Oxygen Consumption Through Attenuation of Contractile Response to {beta}-Adrenergic Stimulation in Patients With Idiopathic Dilated Cardiomyopathy Circulation, April 25, 2000; 101(16): 1925 - 1930. [Abstract] [Full Text] [PDF]

				J. Spinar, J. Vitovec, L. Spinarova, L. Pluhacek, B. Fischerova, and J. Toman A comparison of intervention with losartan or captopril in acute myocardial infarction Eur J Heart Fail, March 1, 2000; 2(1): 91 - 100. [Abstract] [Full Text] [PDF]

				G. Gambassi, K. L. Lapane, A. Sgadari, P. Carbonin, C. Gatsonis, L. A. Lipsitz, V. Mor, R. Bernabei, and for the SAGE Study Group Effects of Angiotensin-Converting Enzyme Inhibitors and Digoxin on Health Outcomes of Very Old Patients With Heart Failure Arch Intern Med, January 10, 2000; 160(1): 53 - 60. [Abstract] [Full Text] [PDF]

				J. B. Young Angiotensin-converting enzyme inhibitors and cytokines in heart failure: dose and effect? J. Am. Coll. Cardiol., December 1, 1999; 34(7): 2068 - 2071. [Full Text] [PDF]

				G R Constantine, J I P Herath, A A P T Chang, P Suganthan, B S L Hewamane, and P N Thenabadu Management of acute myocardial infarction in general medical wards in Sri Lanka Postgrad. Med. J., December 1, 1999; 75(890): 718 - 720. [Abstract] [Full Text]

				E. D. Frohlich The necessity for recognition and treatment of patients with "mild" hypertension J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1369 - 1377. [Abstract] [Full Text] [PDF]

				D. J. van Veldhuisen, S. Genth-Zotz, J. Brouwer, F. Boomsma, T. Netzer, A. J. Man in 't Veld, Y. M. Pinto, K. I. Lie, and H. J. G. M. Crijns High- versus low-dose ACE inhibition in chronic heart failure: A double-blind, placebo-controlled study of imidapril J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1811 - 1818. [Abstract] [Full Text] [PDF]

				F. A. Recchia, P. I. McConnell, R. D. Bernstein, T. R. Vogel, X. Xu, and T. H. Hintze Reduced Nitric Oxide Production and Altered Myocardial Metabolism During the Decompensation of Pacing-Induced Heart Failure in the Conscious Dog Circ. Res., November 16, 1998; 83(10): 969 - 979. [Abstract] [Full Text] [PDF]

				J. B. Young, M. Gheorghiade, B. F. Uretsky, J. H. Patterson, and K. F. Adams Jr. Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials J. Am. Coll. Cardiol., September 1, 1998; 32(3): 686 - 692. [Abstract] [Full Text] [PDF]

				G. Gambassi, P. Carbonin, R. Bernabei, and R. R. Peto Angiotensin-Converting Enzyme Inhibitors for Elderly Patients With Congestive Heart Failure Arch Intern Med, January 12, 1998; 158(1): 97 - 98. [Full Text] [PDF]